Tag Archive for: HER2-positive metastatic breast cancer

Becoming an Empowered and [ACT]IVATED Breast Cancer Patient

Patient Empowerment Network (PEN) is committed to helping educate and empower patients and care partners in the breast cancer community. Breast cancer treatment options are ever-growing with research advancements in treatments and testing, and it’s important for patients and families to educate themselves with health literacy tools and resources on the latest information in breast cancer care. With this goal in mind, PEN kicked off the [ACT]IVATED Breast Cancer program, which aims to inform, empower, and engage patients to stay abreast of up-to-date information in breast cancer care. 

The [ACT]IVATED Breast Cancer program is aimed at newly diagnosed breast cancer patients, yet it is beneficial at any stage of disease. [ACT]IVATED Breast Cancer helps patients and care partners stay in the know about the latest options for their breast cancer, provides patient activation tools to help overcome barriers to accessing care, and powerful tips for self-advocacy, coping, and living well with cancer.

Breast Cancer Disparities

With more focus on disparities in breast cancer outcomes, research studies are starting to reveal actionable information on genetic differences. A recent study uncovered a racial disparity among cancer types that are hormone receptor-negative but HER2-positive. While treatment has been successful in white patient groups, the outcomes have been less successful in Black patient groups. The study also noted key gene mutations in the MAPK pathway occur more frequently in Black patients, which warrants further investigation.

Lisa Hatfield and Dr. Demetria Smith-Graziani

Breast cancer expert Dr. Demetria Smith-Graziani from Emory University School of Medicine shared updates about her breast cancer research. “…what we found is that regardless of the type surgery Black women were reporting more severe pain compared to white women, and so that’s what prompted me to engage in my most recent research project…the reason that I’m looking at those specific set of factors is because there are a number of psychological components to the way that we feel pain, such as anxiety, depression and yes trust that are linked to the way that we experience pain and how severe that pain is and how much that pain affects our lives.

Proactive Steps to Improve Breast Cancer Care

Knowledge gained from research studies can be utilized by patient advocates, and actions can be taken to improve breast cancer care and in the evolution of research efforts for all patients. Dr. Smith-Graziani discussed the importance of clinical trials in driving advancements in breast cancer research and treatments. “…all of the current treatments we have that are FDA-approved were approved because of the results from clinical trials that previous patients participated in…And we won’t get any new advancements in breast cancer treatments and come up with even better, more effective treatments, unless we are able to do more clinical trials with more patients. The other part is that in the past, most of the participants of clinical trials have been pretty much the same, they have been mostly white, mostly have insurance, mostly of a higher socioeconomic status, and those patterns continue today, we are still trying to get the patients in clinical trials to reflect the true population of the United States. And in order to know that clinical trials are effective for everybody, we need to have everybody in those trials.”

Dr. Demetria Smith-Graziani

Dr. Smith-Graziani also explained breast cancer subtypes and why it’s vital for patients to learn about their breast cancer subtype. “When we are looking at the cancer cells under the microscope, we look at specific proteins in these cells, and based on what proteins we see, we designate it as positive or negative for the estrogen receptor, the progesterone receptor, or a protein called HER2. When a cancer expresses the estrogen or progesterone receptor, that means that it feeds off of those hormones that your body makes, and that’s why we refer to it as hormone receptor-positive…And it’s important that we know what subtype of breast cancer you have, because it affects the type of treatment that you can get.”

Learning about family history of cancer is also another key to staying proactive in breast cancer care. Dr. Smith-Graziani explained, “So breast cancer definitely can be hereditary, we are aware of some forms of inherited breast cancers, and we have identified certain mutations in genes that are passed down along family lines, that increase the risk of getting breast cancer…ask your family members about their cancer history so that you’re aware of it, and then ask your oncologist if they recommend genetic counseling or testing.”

Another fundamental step in proactive breast cancer care is for patients to ask about their treatment plan. Dr. Smith-Graziani shared advice for patients. “…in addition to potential side effects are how long is my treatment meaning how long am I going to have to stay in the infusion center if I’m getting an IV medication? Or how many months of treatment do I need to get? And then how much time do I need to take off of work? Am I going to be able to work while getting my treatment, so it’s those little things which aren’t so little that are important to discuss, so that the patients can get the best overall picture about how each treatment will affect them in the short and the long term.”

Dr. Smith-Graziani stressed the value of getting your questions answered and also the value of additional expert opinions. “I think it’s important for patients to be as informed as possible to make sure that they are getting all of their questions answered by their doctor, and if you don’t feel like your questions are getting answered, if you don’t feel like your concerns are being appropriately addressed or acknowledged, please make sure that you get a second or a third opinion and talk to another doctor to see if they can answer your questions.”

[ACT]IVATED Breast Cancer Program Resources

The [ACT]IVATED Breast Cancer program series informs, empower, and engage both the overall community and breast cancer patient groups who experience health disparities. The series includes the following resources:

[ACT]IVATED Expert Interviews

[ACT]IVATED Resources

Though there are breast cancer disparities, patients and care partners can be proactive in educating themselves to help ensure optimal care. We hope you can take advantage of these valuable resources to aid in your breast cancer care for yourself or for your loved one.

[ACT]IVATION Tip:  

By texting EMPOWER to +1-833-213-6657, you can receive personalized support from PENs Empowerment Leads. Whether you’re a breast cancer patient, or caring for someone who is, PEN’s Empowerment Leads will be here for you at every step of your journey. Learn more.


Share Your Feedback:

Create your own user feedback survey

What Treatments Are Available for HER2-Positive Metastatic Breast Cancer?

What Treatments Are Available for HER2-Positive Metastatic Breast Cancer? from Patient Empowerment Network on Vimeo.

What are the differences between HR-positive and HER2-negative metastatic breast cancer? Expert Dr. Demetria Smith-Graziani gives a clear breakdown around the differences and encourages patients to  ask what the available standard treatments are for HER2-positive metastatic breast cancer.

Demetria Smith-Graziani, MD, MPH is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Learn more about Dr. Smith-Graziani.

[ACT]IVATION TIP

“…ask about the HER2 status of your breast cancer and ask about what the available standard treatments are for HER2-positive metastatic breast cancer, as well as potential clinical trial options.“

Download Guide  |   Descargar Guía en Español

See More from [ACT]IVATED Breast Cancer

Related Resources:

Practical Questions About Breast Cancer Treatment Patients Should Ask

Practical Questions About Breast Cancer Treatment Patients Should Ask

An Overview of Breast Cancer Subtypes | Tips for Being Proactive

An Overview of Breast Cancer Subtypes | Tips for Being Proactive

The Role of Immunotherapy for Metastatic Breast Cancer or Relapse
 

Transcript:

Lisa Hatfield:

Dr. Smith, can you explain the difference between HR-positive and HER2-negative metastatic breast cancer? And what promising treatments are available for those types of cancer?

Dr. Demetria Smith-Graziani:

So when we look at the cancer cells under the microscope, we test for different proteins, and one of those proteins is called HER2. Breast cancers that overexpress the HER2 protein are considered to be HER2-positive, and those do not have this overexpression are considered to be HER2-negative.  

For metastatic or stage IV breast cancer, cancers that are HER2-positive, have the option of being treated with HER2-targeted therapy, and that means that we have certain drugs that will seek out the cancer cells that are expressing these HER2 proteins bind to those cells and deliver treatments to those cancer cells that destroy those cancer cells in a more targeted fashion than traditional chemotherapy that tends to destroy all rapidly dividing cells equally.

So my activation tip for patients is ask about the HER2 status of your breast cancer and ask about what the available standard treatments are for HER2-positive metastatic breast cancer, as well as potential clinical trial options. 


Share Your Feedback:

Create your own user feedback survey

An Overview of Breast Cancer Subtypes: Tips for Being Proactive

An Overview of Breast Cancer Subtypes: Tips for Being Proactive from Patient Empowerment Network on Vimeo.

Breast cancer has various subtypes, but what do patients need to know about them? Expert Dr. Demetria Smith-Graziani shares an overview of breast cancer subtypes, what is examined in each type, treatments for some subtypes, and advice for patients to be proactive. 

Demetria Smith-Graziani, MD, MPH is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Learn more about Dr. Smith-Graziani.

[ACT]IVATION TIP

“.. ask, what subtype of breast cancer do I have, and what kinds of treatment would I expect with the subtype of breast cancer?”

Download Guide  |   Descargar Guía en Español

See More from [ACT]IVATED Breast Cancer

Related Resources:

Eliminating Disparities in Breast Cancer | Tips for Navigating Inequities
 
Is My Breast Cancer Hereditary?
 
Noted Racial, Ethnic, and Socioeconomic Disparities In Breast Cancer Outcomes

Noted Racial, Ethnic, and Socioeconomic Disparities In Breast Cancer Outcomes


Transcript:

Lisa Hatfield:

What are the various subtypes of breast cancer?

Dr. Demetria Smith-Graziani:

So we tend to think of breast cancer as being either hormone receptor-positive and HER2-negative, or hormone receptor-positive and HER2-positive or hormone receptor-negative and HER2-positive, or what we call triple-negative. Now, that’s really confusing. So let me take a step back. When we are looking at the cancer cells under the microscope, we look at specific proteins in these cells, and based on what proteins we see, we designate it as positive or negative for the estrogen receptor, the progesterone receptor, or a protein called HER2. When a cancer expresses the estrogen or progesterone receptor, that means that it feeds off of those hormones that your body makes, and that’s why we refer to it as hormone receptor-positive.

When your breast cancer over expresses a particular protein called HER2 that allows us to target your cancer with certain treatments that target HER2-positive cells. When a breast cancer is triple-negative, that means that it is negative for all three of those proteins, it does not have the estrogen receptor, the progesterone receptor, or the HER2 protein. 

And it’s important that we know what subtype of breast cancer you have, because it affects the type of treatment that you can get. So my activation tip is that patients should ask, “What subtype of breast cancer do I have, and what kinds of treatment would I expect with the subtype of breast cancer?”


Share Your Feedback:

Create your own user feedback survey